Benet LZ, Rowland M (1982) Pharmacometrics: a new journal section. J Pharmacokinetic Pharmacodynam 10:349–350

Article  Google Scholar 

Michelet R, Aulin LBS, Borghardt JM, Dalla Costa T, Denti P, Ibarra M, Ma G, Meibohm B, Pillai GC, Schmidt S, Hennig S, Kloft C (2023) Barriers to global pharmacometrics: educational challenges and opportunities across the globe. CPT: Pharmacometrics Syst Pharmacol 12:743–747

CAS  PubMed  Google Scholar 

Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR (2008) Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol 48:632–639

Article  PubMed  Google Scholar 

Gieschke R, Steimer JL (2000) Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokin 25:49–58

Article  CAS  Google Scholar 

Lee WH, Fujiwara M (1971) Pharmacometrics of guinea-pig’s gallbladder in vitro. Taiwan Yi Xue Hui Za Zhi 70:687–696

CAS  PubMed  Google Scholar 

Levy G (1966) Kinetics of pharmacologic effects. Clin Pharmacol Ther 7:362–372

Article  CAS  PubMed  Google Scholar 

Karlsson MO (2016). Big world challenges for pharmacometrics. World Conference on Pharmacometrics, Brisbane, Australia.

Gobburu JVS (2022) Future of pharmacometrics: predictive healthcare analytics. Br J Clin Pharmacol 88:1427–1429

Article  PubMed  Google Scholar 

Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I (2019) Model-informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther 105:899–911

Article  PubMed  Google Scholar 

Hughes DM, Goswami S, Keizer RJ, Hughes M-SA, Faldasz JD (2020) Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population. J Antimicrob Chemother 75:434–437

CAS  PubMed  Google Scholar 

Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, Kashuba ADM, Lee CR, Morbitzer K, Patterson JH, Wiltshire T, Easter J, Savage SW, Powell RJ (2017) Precision dosing: public health need, proposed framework, and anticipated impact. Clin Transl Sci 10:443–454

Article  PubMed  PubMed Central  Google Scholar 

Manolis E, Musuamba FT, Karlsson K (2020) Regulatory considerations for building an in silico clinical pharmacology backbone by 2030. Clin Pharmacol Ther 107:746–748

Article  PubMed  Google Scholar 

Karatza E, Yakovleva T, Adams K, Rao GG, Ait-Oudhia S (2022) Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative. J Pharmacokinetic Pharmacodynam 2022:397–400

Article  Google Scholar 

Mentre F, Friberg LE, Duffull S, French J, Lauffenburger DA, Li L, Mager DE, Sinha V, Sobie E, Zhao P (2020) Pharmacometrics and systems pharmacology 2030. Clin Pharmacol Ther 107:76–78

Article  PubMed  Google Scholar 

van der Graaf PH, Giacomini KM (2020) Clinical pharmacology & therapeutics 2030. Clin Pharmacol Ther 107:13–16

Article  PubMed  Google Scholar 

Bonate PL (2014) Be a model communicator: and sell your models to anyone. KDP Publishing (Amazon), Seattle

Google Scholar 

Lesko, L. J. (2009). Formation of the Division of Pharmacometrics within Office of Clinical Pharmacology at FDA. (https://www.mail-archive.com/nmusers@globomaxnm.com/msg01493.html

Akcha M, Bartels C, Bornkamp B, Bretz F, Coello N, Dumortier T, Looby M, Sander O, Schmidli H, Steimer J-L, Vong C (2021) Estimands—what they are and why they are important for pharmacometricians. CPT Pharmacometrics Syst Pharmacol 10:279–282

Article  Google Scholar 

Jaki T, Gordon A, Forster P, Bijnens L, Bornkamp B, Brannath W, Fontana R, Gasparini M, Hampson LV, Jacobs T, Jones B, Paoletti X, Posch M, Titman A, Vonk R, Koenig F (2018) A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17:593–606

CAS  PubMed  PubMed Central  Google Scholar 

Jaki T, Gordon A, Forster P, Bijnens L, Bornkamp B, Brannath W, Fontana R, Gasparini M, Hampson LV, Jacobs T, Jones B, Paoletti X, Posch M, Titman A, Vonk R, Koenig F (2019) Response to comments on Jaki et al., a proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 18:284–286

Article  PubMed  Google Scholar 

Krause A, Kloft C, Huisinga W, Karlsson MO, Pinheiro J, Bies R, Rogers J, Mentre F, Musser BJ, ASA Special Interest Group on Statistics and Pharmacometrics/ISoP Special Interest Group on Statistics and Pharmacometrics (2019) Comment on Jaki et al., a proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 18:278–281

Article  PubMed  Google Scholar 

Dingemanse J, Krause A (2017) Impact of pharmacokinetic-pharmacodynamic modelling in early clinical drug development. Eur J Pharm Sci 109S:S53–S58

Article  PubMed  Google Scholar 

Lott D, Lehr T, Dingemanse J, Krause A (2018) Modeling tolerance development for the effect on heart rate of the selective S1P1 receptor modulator ponesimod. Clin Pharmacol Ther 103:1083–1092

Article  CAS  PubMed  Google Scholar 

Krause A, Lowe PJ (2014) Visualization and communication of pharmacometric models with Berkeley Madonna. CPT Pharmacometrics Syst Pharmacol 3:e116

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lixoft (2020). Simulx Documentation. (https://simulx.lixoft.com/

R Studio, Inc. (2013). Shiny: Web Application Framework for R. (http://shiny.rstudio.com/

Vlasakakis G, Comets E, Keunecke A, Gueorguieva I, Magni P, Terranova N, Della Pasqua O, de Lange EC, Kloft C (2013) White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation. CPT Pharmacometrics Syst Pharmacol 2:e40

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salas-Vallina A, Alegra J, Fernandez Guerrero R (2018) Happiness at work in knowledge-intensive contexts: opening the research agenda. Eur Res ManagBus Econ 24:149–159

Google Scholar 

Sinek S (2009) Start with why: how great leaders inspire everyone to take action. Penguin, New York

Google Scholar 

Anziano R, Milligan PA (2021) Model informed drug development: collaboration through a common framework. Clin Pharmacol Ther 110:1165–1167

Article  PubMed  Google Scholar 

Barrett JS (2008) The role of quantitative pharmacology in an academic translational research environment. AAPS J 10:9–14

Article  PubMed  PubMed Central  Google Scholar 

Romero K, Corrigan B, Tornoe CW, Gobburu JVS, Danhof M, Gillespie WR, Gastonguay MR, Meibohm B, Derendorf H (2010) Pharmacometrics as a discipline is entering the “industrialization” phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol 50(Suppl 9):9S-19S

Article  PubMed  Google Scholar 

Brundage RC, Pfister M, D’Argenio D, Gastonguay M, Miller R, Tannenbaum S (2010) ACoP: The tools, carpenters, and architects building the discipline of pharmacometrics. J Clin Pharmacol 50(Suppl 9):7S-8S

Article  PubMed  Google Scholar 

Pfister M, Brundage RC, Gastonguay M, Miller R, Tannenbaum SJ, D’Argenio DZ (2010) Defining the future of pharmacometrics: the American Society of Pharmacometrics. J Clin Pharmacol 50(9):158S

Article  PubMed  Google Scholar 

Bruno R, Mentre F, Tannenbaum S, Wang Y, Corrigan B, Mager DE (2014) The ISoP standards and best practices committee. Clin Pharmacol Ther 95:581–582

Article  CAS  PubMed  Google Scholar 

Holford N, Karlsson MO (2007) Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum. Clin Pharmacol Ther 82:103–105

Article  CAS  PubMed  Google Scholar 

Brouwer KLR, Schmidt S, Floren LC, Johnson JA (2020) Clinical pharmacology education—the decade ahead. Clin Pharmacol Ther 107:37–39

Article  PubMed  Google Scholar 

Venkatakrishnan K, Zheng S, Mustante CJ, Jin JY, Riggs MR, Krishnaswami S, Visser SAG (2020) Toward progress in quantitative translational medicine: a call to action. Clin Pharmacol Ther 107:85–88

Article  PubMed  Google Scholar 

Neely M, Jelliffe R (2008) Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol 48:1081–1091

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neely M, Jelliffe R (2010) Individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J Clin Pharmacol 50:842–847

Article  CAS  PubMed  Google Scholar 

Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny J-L, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A (2017) Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future. Clin Pharmacol Ther 101:646–656

Article  CAS  PubMed  Google Scholar 

Vinks AA, Peck RW, Neely M, Mould DR (2020) Development and implementation of electronic health record-integrated model-informed clinical descision support tools for the precision dosing of drugs. Clin Pharmacol Ther 107:129–135

Article  PubMed  Google Scholar 

Zhang L, Allerheilegen SRB, Lalonde R, Stanski D, Pfister M (2010) Fostering culture and optimizing organizational structure for implementing model-based drug development. J Clin Pharmacol 50(9):146S-150S

Article  PubMed  Google Scholar 

Barrett JS, Romero K, Rayner C, Gastonguay M, Pillai C, Tannenba